CNS Pharmaceuticals, Inc. cash flow to debt ratio of -4.20K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

CNS Pharmaceuticals, Inc.'s free cash flow has increased -19.21% from $-17.12M last year to $-13.83M, signaling increasing performance

CNS Pharmaceuticals, Inc.'s debt to equity ratio is 3.29, which means that the company's assets are unhealthy financed, signaling financial risk.

CNS Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.05 last year to 3.29 today, signaling weakened financials

CNS Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

CNS Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

CNS Pharmaceuticals, Inc. has insufficient data to evaluate this check.

CNS Pharmaceuticals, Inc.'s short-term assets of $8.10M exceed its short-term liabilities of $4.10M

CNS Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

CNS Pharmaceuticals, Inc.'s return on equity of -238.69%, is lower than 15.00%, indicating bad performance

CNS Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

CNS Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

CNS Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

CNS Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

CNS Pharmaceuticals, Inc.'s yearly earnings has decreased 6.68% since last year from $-14.86M to $-15.85M, signaling decreasing performance

CNS Pharmaceuticals, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -5.49K% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

CNS Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

CNS Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

CNS Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

CNS Pharmaceuticals, Inc. has insufficient data to evaluate this check.

CNS Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CNS Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

CNS Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

CNS Pharmaceuticals, Inc. has insufficient data to evaluate this check.

CNS Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CNS Pharmaceuticals, Inc. has a price-to-book ratio of 49.04x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

CNS Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue